Cerium Pharmaceuticals is focused on developing innovative therapies for patients suffering from rare kidney diseases, particularly Primary Membranous Nephropathy (PMN). The company is advancing a synthetic form of adrenocorticotropic hormone (ACTH), known as SNP-ACTH (1-39) Gel, which has received FDA Orphan Drug Designation for the treatment of PMN. This investigational drug aims to address the significant health challenges associated with PMN, a condition that can lead to severe kidney dysfunction and a reduced quality of life for patients. Cerium is currently conducting a Phase 3 clinical trial to evaluate the efficacy of SNP-ACTH compared to rituximab, with the trial structured in two parts: Phase 3a, focusing on dose finding, and Phase 3b, assessing the treatment's superiority.

The Phase 3 clinical trial is designed to enroll patients across multiple sites in the United States, Canada, and India, with a comprehensive monitoring plan that includes regular health assessments and laboratory tests. The trial aims to determine the optimal dosing of SNP-ACTH through a risk/benefit analysis based on data collected during the initial phase. By targeting a rare disease with a significant unmet medical need, Cerium Pharmaceuticals is committed to advancing the understanding and treatment of PMN, ultimately striving to improve patient outcomes and quality of life.

United States

Cerium Pharmaceuticals is dedicated to creating efficacious therapies for patients with kidney diseases. Cerium is currently focused on developing the first drug approved for a very rare kidney disease called Primary Membranous Nephropathy (PMN).  There are approximately 75,000 PMN patients in the US and approximately 3,000 newly diagnosed PMN patients per year.

Cerium Pharmaceuticals

Company Details